

**Date:** 10<sup>th</sup> January, 2024

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400 001

Dear Sir / Ma'am,

**Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Export Order of Rs. 136 Crores**

**Ref: Security Id: EVOQ / Code: 543500**

Pursuant to regulations 30 read with Schedule III of the Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015, we would like to inform you that Evoq Remedies Limited ("The Company" or "EVOQ") has received Export order of Rs. 136 Crores from the Marlexx Pharma Inc. to deliver high-quality pharmaceutical products and marks a significant step forward in our business growth.

The details required under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09/09/2015 is enclosed herewith as Annexure-1.

Kindly take the above on record.

Thanking you,

Yours faithfully,

**For, Evoq Remedies Limited**

**Bhumishth Patel**  
**Managing Director**  
**DIN: 02516641**

### Annexure - A

**Details as required under Regulation 30 of the Listing Regulations and the SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, are provided below:**

#### Details of Order received form Marlexx Pharma Inc.

Sr. No.	Particulars	Details
1.	Name(s) of parties with whom order is received.	Marlexx Pharma Inc., incorporated under the appropriate laws of the United States having its office at 65 Lukens Dr, New Castle, DE 19720.
2.	Purpose of this announcement.	Export order worth Rs. 136 Crores.
3.	Shareholding, if any, in entity with whom order is received.	Nil
4.	Significant terms of the order (in brief).	<p>The orders include a range of pharmaceutical APIs valued over Rs. 136 Crores, reflecting Marlexx Pharma Inc.'s confidence in our product offerings.</p> <p>Details of the products:</p> <ol style="list-style-type: none"> <li>1. Metformin API</li> <li>2. Tramadol Hydrochloride API</li> <li>3. Lisinopril API Powder</li> <li>4. Omeprazole Powder API</li> <li>5. CEFOXITIN SODIUM STERILE</li> <li>6. COLISTIMETHATE SODIUM STERILE</li> <li>7. MEROPENEM STERILE</li> <li>8. PIPRACILLIN SODIUM STERILE</li> </ol>
5.	Whether the said parties are related to promoters / promoter Group/ group companies in any manner, if yes, nature of relationship.	No
6.	Whether the transactions would fall within related party transactions? If yes whether the same is done at "arm's length".	No
7.	In case of issuance of shares to the parties' details of issue of price, class of shares issued.	Not Applicable
8.	Any other disclosures related to such order	Export order of Rs. 136 Crores from the Marlexx Pharma Inc. aligned to deliver high-quality pharmaceutical products and marks a significant step forward in our business growth.
9.	In case of termination or amendment of order listed entity shall disclose additional details to the stock exchange(s)	Not Applicable